Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Allakos Inc (ALLK)

Allakos Inc (ALLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 61,025
  • Shares Outstanding, K 88,544
  • Annual Sales, $ 0 K
  • Annual Income, $ -185,700 K
  • 60-Month Beta 0.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.64
Trade ALLK with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.14
  • Most Recent Earnings $-0.50 on 05/09/24
  • Next Earnings Date 08/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 356.92% ( +20.70%)
  • Historical Volatility 93.75%
  • IV Percentile 93%
  • IV Rank 51.65%
  • IV High 684.62% on 07/09/24
  • IV Low 6.90% on 02/29/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 29
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 949
  • Open Int (30-Day) 1,097

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.32
  • Number of Estimates 4
  • High Estimate -0.28
  • Low Estimate -0.36
  • Prior Year -0.41
  • Growth Rate Est. (year over year) +21.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6856 +0.53%
on 07/19/24
1.2200 -43.51%
on 06/24/24
-0.4308 (-38.46%)
since 06/18/24
3-Month
0.6856 +0.53%
on 07/19/24
1.5100 -54.36%
on 05/20/24
-0.3808 (-35.59%)
since 04/19/24
52-Week
0.6856 +0.53%
on 07/19/24
5.6400 -87.78%
on 08/07/23
-4.0208 (-85.37%)
since 07/19/23

Most Recent Stories

More News
Why Shares of Allakos Are Up Wednesday

The stock is bouncing back from a recent 52-week low.

ALLK : 0.6892 (-8.11%)
Why Allakos Stock Skyrocketed Nearly 9% Higher Today

The company is poised to report a critical set of clinical data in the coming months.

ALLK : 0.6892 (-8.11%)
Why Allakos Stock Was Heating Up Today

A notable analyst upgrade had investors piling into this clinical-stage biotech stock today.

PIPR : 258.03 (-0.79%)
ALLK : 0.6892 (-8.11%)
Why Allakos Stock Is on Fire Today

Investors appear to be getting into position ahead of a major upcoming catalyst.

ALLK : 0.6892 (-8.11%)
Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results

SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...

ALLK : 0.6892 (-8.11%)
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...

ALLK : 0.6892 (-8.11%)
INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.– ALLK

The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by the management of Allakos, Inc. (“Allakos”) (NASDAQ: ALLK...

ALLK : 0.6892 (-8.11%)
INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.– ALLK

The Schall Law Firm, a national shareholder rights litigation firm, announces it is investigating potential breaches of fiduciary duties by the management of Allakos, Inc. (“Allakos”) (NASDAQ: ALLK...

ALLK : 0.6892 (-8.11%)
Allakos Provides Business Update and Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab...

ALLK : 0.6892 (-8.11%)
Why Allakos Stock Sank 17.3% in February

The biotech stock has lost roughly 96% of its value over the last year.

ALLK : 0.6892 (-8.11%)

Business Summary

Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 0.8710
2nd Resistance Point 0.8332
1st Resistance Point 0.7612
Last Price 0.6892
1st Support Level 0.6514
2nd Support Level 0.6136
3rd Support Level 0.5416

See More

52-Week High 5.6400
Fibonacci 61.8% 3.7474
Fibonacci 50% 3.1628
Fibonacci 38.2% 2.5782
Last Price 0.6892
52-Week Low 0.6856

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar